Just caught Akzo Nobel's Q4 results and there's an interesting disconnect worth unpacking here. Their net income basically exploded to 598 million euros versus just 21 million last year, with EPS jumping to 3.50 euros. Looks impressive on the surface, right? But here's where it gets nuanced - the adj operating income actually fell 4% to 217 million euros, and more telling, adj EBITDA dropped 4% to 309 million euros despite the headline profit surge.

The revenue story explains some of it - top line contracted 9% to 2.37 billion euros in Q4, with organic sales down 1% from lower volumes. So you're looking at a company navigating pretty weak demand across their end markets. The paint and coatings space clearly isn't firing on all cylinders right now.

But here's what caught my attention: despite the revenue pressure, their adj EBITDA margin actually improved to 13.0% from 12.3%. That's the efficiency story kicking in. Management's clearly been executing on cost controls and operational improvements, which is helping them maintain profitability even as volumes soften.

Looking at the full year 2025, adj EBITDA came in at 1.44 billion euros (down 2%), with revenues falling 5% to 10.16 billion euros. They maintained their dividend at 1.54 euros per share, which signals confidence despite the headwinds.

For 2026, the company is guiding for adj EBITDA at or above 1.47 billion euros - that's roughly 100 million euros of improvement in constant currencies. CEO Greg Poux-Guillaume was pretty candid in the statement: they're not expecting a material recovery across end markets in 2026, anticipating a weak first half before easier comparisons kick in during the second half. The efficiency measures will be key to hitting those targets.

Mid-term, they're targeting an adj EBITDA margin above 16% with return on investment between 16-19%. That's a meaningful jump from current levels, but shows where management believes they can take this business operationally.

One more thing to watch - the Axalta merger closing is expected late 2026 or early 2027, pending approvals. That's another variable in the mix. For now, the story seems to be about operational excellence offsetting market weakness. Worth monitoring how the efficiency playbook holds up if demand stays soft.